U.S. Platelet Rich Plasma Market Size, Share, Growth, Trends, Company Analysis, Regional Insights and Forecast 2020 - 2027

The U.S. platelet rich plasma market size is expected to reach around USD 364.1 million by 2027, according to a new report by Vision Research Reports.

The U.S. platelet rich plasma market size was valued at USD 165 million in 2019 and is expected to grow at a CAGR of 10.1% from forecast period 2020 to 2027.

Platelet-rich plasma (PRP) has gained significant popularity in the field of orthopedics, neurosurgery, ophthalmology, and cosmetic surgery as it integrates modern technology with the body's capability to accelerate healing. A rise in the incidence of musculoskeletal disorders, orthopedic disorders, and sports injuries has encouraged clinicians to embrace minimally invasive platelet rich plasma therapy with less risk of therapy-associated adverse effects, which propels the market growth.

Report Study

  • Pure platelet rich plasma dominated the market with a revenue share of 52.1% in 2019.
  • The leukocyte-rich platelet rich plasma segment is expected to witness a significant increase in the commercial pool and number of experimental studies expanding its applications across orthopedic, general surgery, and sports medicine

  • Numerous advancements in leukocyte PRP market space by manufacturers, mainly in protocol automation to maximize the standardization of plasma preparations are driving the segment

  • In terms of revenue, the orthopedics held the maximum share of 22.6% in 2019 in the U.S. Platelet Rich Plasma (PRP) market.
  • The cosmetic surgery and dermatology application segment is expected to foresee the highest growth rate during the overcast period

  • The hospital segment accounted for the largest revenue share of 49.6% in 2019 with a substantial number of hospitals in the U.S. that provide PRP-based therapies.
  • This is due to a rapid increase in preference among the consumers as injections based on this therapy help to achieve fuller facial features without opting for commercial fillers

  • Platelet rich plasma systems are estimated to witness the fastest growth rate throughout the forecast period in the sports medicine application

  • The advent of novel separation systems by key manufacturers that are specific to platelet rich plasma applications as well as functions vertically and are applicable across autologous cellular therapies boost the growth of these systems

  • Numerous medical visits, high burden of orthopedic disorders particularly in geriatric population, and widespread application of this therapy for musculoskeletal injuries result in the dominant share of hospitals in 2019

  • More than 300,000 old aged people, over 65 years, are hospitalized for hip fractures every year in the U.S.

  • This high hospitalization rate surges the incorporation of platelet rich plasma as an adjunctive use in hip surgeries in hospital settings

  • Key manufacturers are implementing business strategies such as broadening of product portfolio, widening of distribution network, and collaborations and mergers to reinforce their significant share in the market.

Some of the prominent players are:

  • DePuy Synthes (Johnson & Johnson)

  • Arthrex, Inc.

  • EmCyte Corporation

  • Dr. PRP America LLC

  • Juventix Regenerative Medical

  • Terumo BCT, Inc.

  • Zimmer Biomet

  • Stryker

Market Segmentation

Type Outlook

    • Pure PRP

    • Leukocyte Rich PRP

    • Others

Application Outlook

    • Orthopedics

    • Sports Medicine

      • PRP Injections

      • PRP Kits

      • PRP Systems

    • Cosmetic Surgery and Dermatology

    • Ophthalmic Surgery

    • Neurosurgery

    • General Surgery

    • Others

End-use Outlook

    • Hospitals

    • Clinics

    • Others

Report Detail

Proceed To Buy

USD 3500
USD 6000